Home » Topics » BioWorld Science

BioWorld Science
RSS

Fate Therapeutics gives update on phase I study of FT-500

April 5, 2019

Phase I results of highly selective dual IDO1/TDO2 inhibitor M-4112 in advanced solid malignancies

April 4, 2019

Comparison of the novel biguanide NT-1195 with metformin/phenformin in endometrial cancer models

April 4, 2019

Preclinical results of EI-1071, a selective CSF1R inhibitor regulating tumor-associated macrophages

April 4, 2019

Bluevalley Pharmaceutical discloses ATR inhibitors

April 4, 2019

U.S. researchers synthesize antisense oligonucleotides targeting MYC

April 4, 2019

TNFRSF18-targeting shRNAs described in Shenzhen Biocan Technologies patent

April 4, 2019

Shenzhen Biocan Technologies identifies new IDO-targeting shRNAs

April 4, 2019

Shenzhen Biocan Technologies patents APP-targeting shRNAs

April 4, 2019

Stem cell-derived human 'hearts' identify new cardiac drugs

April 4, 2019

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...